NDLI: Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Content Provider	Springer Nature : BioMed Central
Author	ten Hoorn, Sanne Waasdorp, Cynthia van Oijen, Martijn G. H. Damhofer, Helene Trinh, Anne Zhao, Lan Smits, Lisanne J. H. Bootsma, Sanne van Pelt, Gabi W. Mesker, Wilma E. Mol, Linda Goey, Kaitlyn K. H. Koopman, Miriam Medema, Jan Paul Tuynman, Jurriaan B. Zlobec, Inti Punt, Cornelis J. A. Vermeulen, Louis Bijlsma, Maarten F.
Abstract	Background Recently it has been recognized that stromal markers could be used as a clinically relevant biomarker for therapy response and prognosis. Here, we report on a serum marker for stromal activation, A Disintegrin and Metalloprotease 12 (ADAM12) in colorectal cancer (CRC). Methods Using gene expression databases we investigated ADAM12 expression in CRC and delineated the source of ADAM12 expression. The clinical value of ADAM12 was retrospectively assessed in the CAIRO2 trial in metastatic CRC with 235 patients (31% of total cohort), and an independent rectal cancer cohort (n = 20). Results ADAM12 is expressed by activated CRC associated fibroblasts. In the CAIRO2 trial cohort, ADAM12 serum levels were prognostic (ADAM12 low versus ADAM12 high; median OS 25.3 vs. 17.1 months, HR 1.48 [95% CI 1.11–1.96], P = 0.007). The prognostic potential was specifically high for metastatic rectal cancer (HR 1.78 [95% CI 1.06–3.00], P = 0.030) and mesenchymal subtype tumors (HR 2.12 [95% CI 1.25–3.60], P = 0.004). ADAM12 also showed potential for predicting recurrence in an exploratory analysis of non-metastatic rectal cancers. Conclusions Here we describe a non-invasive marker for activated stroma in CRC which associates with poor outcome, especially for primary cancers located in the rectum.
Related Links	https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-022-09436-0.pdf
Ending Page	11
Page Count	11
Starting Page	1
File Format	HTM / HTML
ISSN	14712407
DOI	10.1186/s12885-022-09436-0
Journal	BMC Cancer
Issue Number	1
Volume Number	22
Language	English
Publisher	BioMed Central
Publisher Date	2022-04-12
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Surgical Oncology Health Promotion and Disease Prevention Biomedicine Medicine Public Health Colorectal cancer Prognostic marker ADAM12 Stroma Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology Genetics
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Podocalyxin is a marker of poor prognosis in colorectal cancer

Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients

Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer

Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis

The prognostic significance of tumour-stroma ratio in endometrial carcinoma

The prognostic significance of the postoperative prognostic nutritional index in patients with colorectal cancer

Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma

High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer

Elevated expression of AGGF1 predicts poor prognosis and promotes the metastasis of colorectal cancer

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Similar Documents

Podocalyxin is a marker of poor prognosis in colorectal cancer

Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients

Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer

Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis

The prognostic significance of tumour-stroma ratio in endometrial carcinoma

The prognostic significance of the postoperative prognostic nutritional index in patients with colorectal cancer

Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma

High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer

Elevated expression of AGGF1 predicts poor prognosis and promotes the metastasis of colorectal cancer

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer